Blogs
Healthcare and Medtech Research Reports
Sep 11, 2026
Summary For decades, moderate-to-severe atopic dermatitis (AD) was managed with topical steroids, calcineurin inhibitors, and broad immunosuppressants, until targeted biologics transformed care. Two biologics dominate: DUPIXENT (dupilumab) by Sanofi/Regeneron and ADBRY (tralokinumab) by LEO Pharma; both targ...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper